Bleeding disorders : functionality of global haemostasis assays in attaining clinical outcomes : a review by Maule, Warren J.
ISSN 1011 5528  |  www.smltsa.org.za  5
Volume 30 No. 2  |  December 2016Medical Technology SA
Peer reviewed REVIEW
Bleeding disorders: functionality of gloBal haemostasis 
assays in attaining clinical outcomes: a review
WJ Maule CSci, F.I.B.M.S.
University of Johannesburg, Department of Biomedical Technology, Faculty of Health Sciences, South Africa.
The material in this Biomedical Science review paper submitted to the Medical Technology Journal SA, has neither been published, nor is 
being considered elsewhere for publication.
Correspondence: Warren Maule | tel: +27 (0)82 056 9925, +27 (0)11 764 5418 | email: warrenm@uj.ac.za
SUMMARY
Many tests used to evaluate haemostasis correspond to artificially created environments. These include some of the traditional 
screening tests, which were established through understanding the coagulation cascade for example, the prothrombin time (PT), 
the activated partial thromboplastin time (aPTT) and Fibrinogen estimation. And as such, they have contributed greatly to our cur-
rent knowledge of the haemostatic process. Unfortunately, these traditional laboratory tests have their limitations. Open to debate 
for example, is their ability to supply enough information timeously (? laboratory turnaround time) in order to diagnose and treat 
patients according to their phenotype.
Anarchetypical shift in haemostasis measurements using global haemostasis tests that determine the complete process in a more 
physiological and all-inclusive way are consequently being reevaluated.
These tests include: 
• The viscoelastic tests (ROTEM/TEG) improve the treatment of acute haemorrhage, decreasing the transfusion burden, as for 
example in cardiac surgery and with it a more effective use of blood and blood products, thus lowering overall costs. They also 
provide rapid, comprehensive and accurate identification of an individual’s haemostasis state, in the laboratory or in the context 
of near-patient testing as point-of-care instruments. This allows clinicians to drive personalised, clinically and economically 
sound treatment and monitoring decisions.
• Thrombin generation measurement; although expensive is elegant. And as well as having an important role in managing haem-
orrhage it may be sensitive to various factors that contribute to hypercoagulation. The test may also be of value in discriminating 
between the different phenotypes within the population of severe haemophilia A (HA) patients. It is here to stay.
• The clot waveform analysis may be less well known (i.e. presently used as a research tool). It shows promise in staging sepsis 
patients, having a role in the early detection of disseminated intravascular coagulation (DIC) and also in the diagnosis and 
treatment-monitoring of haemophiliac patients.
• Flow perfusion chambers which while they may be the ‘ultimate’ global assay has a considerable way to go in order to become 
of use clinically.
Although global haemostasis tests have been available for some time, there is a renewed awareness in their potential use for as-
sessing both normal and abnormal haemostasis. Initial data suggests that they can provide more detailed information regarding the 
overall haemostatic process and its disorders. However, many challenges still remain such as with the analysers themselves. These 
involve their trademarked technology, their expense and finally their availability.
All four methods still need more background standardisation regarding reagents, methodologies and finally interpretation of results. 
Much more additional information is required involving all the parameters measured and by inference, their subsequent clinical 
applications. The present review describes these various global haemostasis tests giving some background information, as well as 
clinical outcomes and lastly some information on their limitations.
INTRODUCTION
In humans, the haemostatic processes exist as defence mecha-
nisms against both bleeding and thrombotic tendencies. 
Haemostasis is a normal physiological process that maintains 
blood in a fluid clot-free state while inducing a haemostatic 
plug at the site of vessel injury. Thrombosis is the inappropri-
ate activation of haemostatic mechanisms in uninjured vessels. 
Together these complex processes are dependent on a number 
of well-orchestrated interactions between the following: the en-
dothelium, platelets and finally the coagulation and fibrinolytic 
mechanisms.
The complexity of this system is evident from the variable re-
sponses of patients when haemostasis is challenged. This can 
occur when disturbances in the balance between the pro-
coagulant system (amplification) and the anticoagulant system 
(natural inhibitors) result in bleeding or thrombotic diseases.[1]
Haemostasis
Haemostasis when threatened, enables the individual (no mat-
ter what genus) to: seal injured blood vessels; keep the blood 
in a liquid condition and to remove blood clots after the repair 
of vascular integrity. The Greek philosopher Plato two millennia 
ago[2] described ‘that the blood formed fibres once it left the 
heat of the body’. Amazingly, he was the first to perceive the 
term fibrin, which today refers to a significant blood clotting 
protein that comprise those fibre structures.[1,2] Hewson[3] in the 
1770s isolated the source of these fibres to what he named the 
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‘coagulable lymph’, the straw-coloured liquid part of the blood 
we now call plasma .It was not until 1865, when platelets were 
discovered as well as their crucial function in the overall hae-
mostatic process.[4]
In 1905, Morawitz[5] created the first coagulation model in 
which thromboplastin, now known as tissue factor (TF), was 
released by damaged vessels to convert prothrombin (II) into 
thrombin (IIa) in the presence of calcium (Ca++).[6]
In the formation of the blood clot, thrombin (IIa) converts solu-
ble plasma fibrinogen (I) into insoluble fibrin. This 4-clotting 
factor model however, could not fully explain the multifaceted 
process of coagulation
The overall response to a threat to the haemostastic process can 
now be divided into primary and secondary haemostasis. 
• Primary haemostasis consists of vasoconstriction, platelet 
adhesion and activation, with the ultimate formation of the 
platelet plug.
• Secondary haemostasis involves serine protease zymogens 
(coagulation factors) which interact with their co-factors in 
a tightly regulated sequence to form cross-linked fibrin that 
helps in stabilising the initial unstable platelet plug. This is 
an exceptionally ordered process and is the result of numer-
ous reactions.[7,8]
In the 1960s ‘the coagulation cascade’ was identified and de-
scribed by two separate groups as the processes involved in 
the secondary haemostasis response.[8-10] Herein, one of the es-
sential features of this cascade is the sequence of the number 
of steps required in its activation. It is an extremely complex 
process and is reliant on both negative and positive feedback 
loop mechanisms to ensure that the haemostatic response is in 
balance, i.e. without haemorrhage or thrombosis occurring.
Coagulation Cascade
The coagulation cascade consists of a number of clotting factors, 
which have been organised into extrinsic, intrinsic and common 
pathways,[1,11,12] and are of importance in the laboratory when 
assessing a defect in the haemostatic process (see Figure 1).
While it is commonly referred to as a cascade, in reality these 
pathways are not separate entities but are better interpreted as 
a network, involving numerous interlinked reactions that are 
closely involved in the regulation of this essential physiological 
process.
Abnormalities in the haemostatic process have been tradition-
ally evaluated using plasma clotting times, such as the PT and 
the aPTT.[13]
These tests are dependent on the initiation of the process of 
fibrinogen to fibrin and not on its speed or total extent. Factor 
assays based on these tests have identified the different coagula-
tion disorders including for example, haemophilia A (HA).[14,15]
Unfortunately there are a number of limitations to these tests. 
These include the following: all are performed under unreal 
physiological conditions that split the process of coagulation 
into artificial segments. In general, they don't evaluate the po-
tential effect of different parts of the haemostatic framework. 
Factor assay’s performed utilising either the PT or aPTT are lim-
ited by their general affectability at low levels.[16] For instance, 
the plasma from a few patients with extreme HA can produce 
thrombin.[17] The accurate premise for this is not known, but it 
may be because of the equalisation of levels of both distinctive 
procoagulant and anticoagulant proteins in the blood.[18]
Global Haemostasis Assays
In routine clinical practice the PT and aPTT tests are used to 
evaluate a patient’s haemostatic potential and prolongation of 
either or both of these assays is interpreted as evidence of an 
anticoagulated state. However, there is some debate about how 
useful these tests are in assessing haemostasis in chronic liver 
disease,[19,20] which could further extend to their usefulness in 
assessing haemostasis in congenital haemostatic defects.
In particular, critically ill patients who have prolonged routine 
coagulation screens, but do not show any overt signs of bleed-
ing,[21] these screening tests (i.e.PT and aPTT) do not appear to 
reflect the actual bleeding risk.[22] In this regard other assays are 
required to determine a patient’s haemostatic potential.
Global haemostatic tests have the ability to contribute addition-
al information in terms of assessing bleeding,[21] particularly in 
Figure 1: The coagulation cascade with arrows for positive and negative feedback loops. Adapted from.[1]
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those patients known to have a poor response to a haemostatic 
challenge.
In vitro investigations have demonstrated the phenomenon, 
that during the initiation phase of coagulation, very low lev-
els of thrombin are needed for the formation of the fibrin clot, 
which in fact is visible when only 3-5% of the total amount 
of thrombin has been produced.[23] Therefore, the conventional 
tests that use these fibrin-clotting endpoints are limited in their 
usefulness in assessing haemostasis, particularly in individuals 
that have impairment in their blood clotting capability as for 
example, HA patients.
Low concentrations of tissue factor and the rate of thrombin 
generation are essential in the formation of a stable fibrin clot.[24] 
This essential process is highly regulated through feedback 
mechanisms in which thrombin itself plays an important role, in 
controlling its own production and destruction.[25]
Model coagulation tests should be easy to perform, in that they 
should be able to obtain reliable and robust results quickly. 
Overall, all assays aligned with the haemostatic mechanism 
should give accurate estimates of thrombotic risk as well as the 
risk of bleeding.
To-date there is no widely available standardised tests that can 
quantitatively assess the overall haemostatic potential of the 
blood.
Global haemostasis assays are in vitro models of haemostasis 
and thrombosis that aim to mimic most important aspects of 
the physiological and pathological system of haemostasis, how-
ever it should be highlighted that no single test can fulfill this 
requirement.
These tests include the following: thrombin generation tests/
assay (TGT/TGA, CAT),[26,27] thromboelastography (TEG, RO-
TEM),[28,29] the clot waveform analysis (CWA)[30,31] and finally 
flow perfusion chambers.[32]
ThROMbIN gENERATION TESTS
Calibrated, automated thrombogram (CAT)
Thrombin generation is one of the best developed and tested 
global assays of haemostasis. Hemker et al established the con-
ceptual methodology of the CAT method.[33,34] Using the CAT 
system, changes in the amount of thrombin generated in the 
presence of fibrin(ogen) following a given tissue factor stimulus, 
can be visualised continuously using a thrombin sensitive fluor-
ogenic substrate. The definitive thrombin generation curve has 
a waveform form, from which a series of quantified parameters 
can be calculated i.e. (lag time, thrombin generation velocity, 
peak thrombin concentration, time-to-peak thrombin and en-
dogenous thrombin potential (ETP),[35] Figure 2.[36])
Commercially available semi-automated analysers, can be used 
to perform a thrombin generation assay (TGA) that produces 
the definitive thrombin generation curves that may prove to be 
of use in screening defects in haemostasis.[37] Such analysers 
rely on fluorogenic or chromogenic principles. Fluorogenic as-
says are supplied by Stago, Kat-Medical, Florida North, South 
Africa (S.A.) and Technclone. Chromogenic assaysare supplied 
by Dade Behring and other customised tests such as the Novel 
Haemostasis Assay from the Radbund University Medical Cen-
tre, Nijmegen, The Netherlands.
Correlation of thrombin generation with clinical phenotype
After its initial use in research the TGA showed increased 
thrombin generation in thrombophilic states such as venous 
thrombosis due to deficiency (e.g. anti-thrombin (AT), protein 
C or S deficiency) as well as due to activated prothrombin com-
plex concentration (APCC)-resistance and the antiphospholipid 
syndrome.[38,39]
TGAs have also been used for laboratory characterisation of 
a variety of bleeding disorders. HA is the best-characterised 
haemostatic abnormality demonstrated by thrombin generation 
profiles, as its rate-specific characteristics have been reported 
to demonstrate and reflect the clinical heterogeneity of the 
disease.[40-43] The TGA may describe the bleeding tendency and 
therefore the risk of bleeding better than the traditional tests. 
However, what is still a matter of debate is the feasibility of us-
ing the TGA to monitor bypassing agent therapy in haemophili-
acs with inhibitors in order to improve clinical outcomes.[44-47]
Additionally, increased thrombin generation is associated with 
Figure 2: Normal thrombin generation curve. The major parameters (lag time, time to peak thrombin generation, 
peak thrombin generation and endogenous thrombin potential) of the thrombin generation curve as shown.  
As reference, a patient with severe HA, which shows that all three parameters are severely affected. (Adapted from[35])
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arterial thrombosis such as ischaemic attack and with the acute 
coronary syndromes.[48,49] In these situations assessment of the 
TGA might be of help in guiding therapy with antithrombotics 
whilst trying to avoid bleeding.
Unfortunately, there are some disadvantages of the TGA assay. 
One of the major drawbacks is its unsuitability in emergency 
cases due to the duration time of the test. Another major issue 
of concern is in the standardisation of the TGA for broad clini-
cal use. This lack of standardisation is due to the large variance 
caused by pre-analytical variables and the lack of reference 
ranges for specific conditions, which impedes its approval as a 
routine clinical tool.[50,51]
Viscoelastic assays (thromboelastography/thromboelastom-
etry)
The most direct way to characterise clot formation is by rheom-
etry, which is unaffected by optical phenomena and is easily 
applied to whole blood.
A number of rheological approaches exist, but perhaps the 
best studied is thromboelastography (TEG). It detects changes 
in the viscosity and elasticity during the clotting process of 
whole blood and has been used to study haemostatic abnor-
malities [52,53] and access whole-blood clotting dynamics. The 
measurements are displayed as a graph, from the beginning of 
clot formation to fibrinolysis. Figure 3 illustrates the association 
of TEG with routine screening tests of haemostasis.
The method is relatively simple and has been used extensively 
for evaluating the amount of fibrin polymerisation and general 
clotting function. As it can be performed on whole blood, it is 
used widely during surgical procedures where there is a high 
risk of bleeding.[54,55] The TEG is analogous to clotting in vivo, 
where cellular blood components (e.g. platelets) contribute sig-
nificantly to thrombin generation at the site of bleeding.
The TEG uses a sample cuvette filled with anticoagulated whole 
blood to measure kinetics, strength, stability and the tensile 
strength of the eventual blood clot. Analysers from Haemonet-
ics®, including the TEG 6s, are available from Barker Medical 
(Pty) Ltd, Broadacres, Johannesburg S.A. TEG 6s assays are per-
formed in automatically loaded microfluidic cartridges (as op-
posed to a sample cup) designed for simultaneous performance 
of multiple TEG assays. 
A pin suspended from a torsion wire is lowered into a cuvette 
and the cup is rotated over a set period of time. Torque from the 
rotating cup is transmitted from the pin to a recorder. The torque 
increases exponentially as the clot forms (see Figure 5).
The whole coagulation profile is then displayed as a thromboe-
lastograph. The overall shape of the graph is determined by the 
blood viscoelastic property and the functional activity of the 
blood components. Sample TEG tracings are shown in Figure 4, 
which illustrates normal and abnormal results.
The method has significant disadvantages however, including 
instability—a freshly collected blood sample is required for 
analysis—poor reproducibility is also of concern. 
While it is sensitive to defects in platelet aggregation and fi-
brinolysis, it is not sensitive in assessing platelet adhesion. 
There are still some trepidations concerning the standardisa-
tion of these assays. Of late a study on quality control and 
assurance showed a wide variation of TEG results between 
different institutions when compared to plasma sample analy-
sis. Based on these results a working group was established 
in order to try and normalise the variability of the test.[56,57]
More recently, a variation of TEG, the rotating thromboelastom-
etry (ROTEM), has been developed.
Rotating Thromboelastometry
Rotating thromboelastometry is a whole-blood clotting test that 
measures the interactions of coagulation factors and their in-
hibitors with cellular components (i.e. red blood cells, platelets) 
during clotting and fibrinolysis over 60 minutes (see Figure 6). 
The test uses similar principles to TEG, originally developed by 
Hartert[58] in which the pin oscillates instead of the cup and as-
sesses the viscoelastic properties of clot formation under low 
shear stress.[59] As with TEG the main drawback of the method 
is its unsuitability in the acute setting due to its long sample 
processing time.
Clot waveform analysis (CWA)
CWA is founded on one of the well-established screening tests; 
the aPTT assay. Braun and co-workers were the first to report 
this technique after assessing the aPTT and PT with light trans-
mission.[60] A graph is created over a protracted period of time 
instead of a standard clotting time as for the aPTT. This graph or 
tracing against time should indicate the whole process of clot 
Figure 3: The relationship between a normal TEG and above the normal screening tests of haemostasis, the PT and aPTT (intrinsic-extrinsic). 
The PTT and aPTT only provide information on the initiation of clot formation, which is similar to that given by the R of the TEG. Adapted from.[53]
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formation terminating inclot lysis (see Figure 7). The necessity of 
standardisation requires that some specific reagents are required 
that do not interfere with light transmission/absorbance.[61]
Despite this need for standardisation, there are two possible 
clinical applications for CWA.
CWA has the potential to monitor patients with disseminated 
intravascular coagulation (DIC), a disease, frequently seen in 
critically ill patients. DIC can also be diagnosed with high spe-
cificity (97.6%) and sensitivity (98%) using CWA as a global 
assessment tool.[62,63] CWA may also be able to detect the DIC 
much earlier than when using conventional clotting assays in 
up to 19% of cases examined. It is therefore recommended by 
the guidelines for diagnosis and treatment of DIC.[64]
CWA seems sensitive to even mild deficiencies (FXII, X, IX, VIII, 
VII, V and II). Taking this into account the assay gives informa-
tion on haemophiliacs, where it might help to distinguish be-
tween haemophilia A and B. 
CWA also gives information on the clinical phenotype with re-
gard to bleeding tendency. And as such it can be used to moni-
tor the effectiveness of Factor VIII infusions in HA patients as 
well as bypassing reagents such as APCC or rFVIIa in patients 
demonstrating inhibitors.[65,66] CWA analysers are available from 
Siemens S.A.
A few authors questioned the use of CWA in assessing critically 
ill patients suffering from sepsis. They subsequently demon-
strated that the severity and the prognosis of the disease can be 
predicted using this global assessment tool.[67,68]
The CWA may be relatively inexpensive and easy to perform but 
unfortunately there are some disadvantages inhibiting its wide 
use in a clinical setting.
There are only two systems currently that are able to measure 
the light transmittance or absorbance tracings. It should be pos-
sible however, to create the necessary graphs from analysers 
that use similar principles after updating their software. 
Figure 6: An illustration of a ROTEM output showing clot initiation, propagation, stabilisation and lysis.[53]
Figure 5: A representation of a normal TEG output as compared to those 
seen in abnormal coagulopathies.[53]
Figure 4: A representation of a TEG device where a pin suspended from a torsion 
wire is immersed in a cup of whole blood. Note that the cup is held in a heating 
block and is continually oscillated through 4-45o every 5 sec. Changes in the 
viscoelastic strength of the clot are directly transmitted to the torsion wire and are 
detected by an electromagnetic transducer.[53]
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One of the major obstacles in using CWA is in the use of totally 
transparent reagents that do not interfere with the light beam.
Obviously, samples with, lipaemia and/or hyperbilirubinemia 
and/or haemolysis will cause interference and as such the test 
results will be invalid.[61]
Another area of concern is in the lack of experience with the 
CWA assay where the parameters are relatively unknown. Addi-
tionally, there is very little information in the literature in regard 
to clinical validation.
Flow or perfusion chambers
There has been a great deal of progress made over the past 
two decades regarding the development of flow chambers and 
micro capillaries to monitor and study thrombus formation in 
vitro. Platelets play a vital role in the occlusion of injuries to the 
vascularity in order to arrest and prevent profuse bleeding. Their 
ability to rapidly adhere to the subendothelial matrix proteins 
(primary adhesion response) and then to subsequently form a 
stable plug reinforced by the coagulation system is central to 
overall haemostatic function.[69,70]
Improvements in microscope technology, with high-resolution 
cameras and the high capacity to store digital images makes it 
possible to study in ‘real’ time the formation of platelets-and-
fibrin thrombi in flow chambers. Potentially this is the ‘ulti-
mate’ global assay in that it is able to determine both platelet 
function/s (including adhesion, aggregation and finally proco-
agulant activity) and blood coagulation.
As such an increasing number of laboratories are using custom-
made or commercial flow chamber devices for (semi-routine) 
testing of impaired or increased platelet function under flow 
conditions to detect for example, hypercoagulation changes 
in blood.[71-75] Unfortunately, there are very few clinical stud-
ies and the standardisation status of these various chambers is 
sadly lacking.[76]
CONClUSION
Unfortunately, the traditional coagulation tests based on clot 
formation do not provide all the information that clinicians may 
require, in order to diagnose and treat haemostatic defects ef-
fectively.
Global haemostasis tests such as TEG/ROTEM, TGA and CWA 
have the potential to reassess the haemostatic mechanism from 
new perspectives. The TEG/ROTEM tests have been shown to 
be meaningful in the management of acute haemorrhage. Data 
from the literature have demonstrated that TEG is part of the 
whole picture of patient blood management strategies and can 
effectively:
• Reduce blood products usage (FFP, RBC, platelets, cryopre-
cipitate).[78]
• Improve adequate use of expensive pharmaceuticals (rFVIIa, 
fibrinogen).
• Allow for the stratification of the risk of thrombosis.
• Reduce hospital stay related costs (ICU length of stay, re-
exploration, adverse reactions to blood transfusions, blood 
product waste, thrombotic episodes).[79]
• There is a growing body of evidence supporting the utility of 
TEG in predicting bleeding.[80]
• However, the utility of TEG in guiding the management of 
post-operative bleeding has been the main driver of adop-
tion.[81]
• Additionally, TEG can identify hypercoagulable states in 
conditions such as acute coronary syndrome, trauma, ob-
stetrics, liver transplant, cancer and stroke.[82-84]
The TGA is of value in thrombotic risks (venous and arterial) 
where the sensitivity to hypercoagulation is definitely higher 
than that of the traditional INR and aPTT tests. Additionally it 
may be a significant instrument in haemostatic therapy.
CWA although less well known demonstrates increasing evi-
dence that it may be of value in improving the diagnosis and 
treatment of DIC, sepsis and haemophilia.
However, there is one major problem that complicates the use 
of global assays in a clinical setting and that is their lack of 
standardisation. Results from a diversity of papers cited in this 
review highlight the difficulties in interpretation and reproduc-
ibility throughout the spectrum of global assays that are cur-
rently available.
Attempts at standardisation through independent groups as well 
as the Scientific and Standardisation Committee of the Interna-
tional Society of Thrombosis and Haemostasis are ongoing. 
The present efforts at standardisation of the more established 
global assays such as the TEG and TGA,[50,51,77,79,83] give hope 
that there could be major paradigm shifts in the way we assess 
and evaluate haemostasis disorders in the future.
Figure 7: aPTT clot curve and its derivatives. The aPTT curve shows the changes in light scatter against time in secs. Adapted from.[61]
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